Hemangi Chaudhari

Computational Biology Scientist

[Hemangi Chaudhari @hemangi_c]

@DesSidDes @CUAnschutz Congratulations!!

[CRISPR Therapeutics @CRISPRTX]

#Breaking: The European Commission approves CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia for the European Union. Learn more: https://t.co/94JrUPfhMT

[Hemangi Chaudhari @hemangi_c]

@gdstormo Congratulations!!

[Hemangi Chaudhari @hemangi_c]

@SelFdz @areyesq I will take one, please!

[Fyodor Urnov @UrnovFyodor]

!!!!!!!!!!!

https://t.co/oHTy502SOd

[Ben Kleinstiver @BKleinstiver]

Register for this *FREE* virtual symposium with a stellar lineup of pioneering speakers!
Come learn about the challenges & progress in the gene editing field!!
🧬🔧🎖️
@lab_davidson @skathire @davidrliu & many others!

[Hemangi Chaudhari @hemangi_c]

@KyleCottrell @PurdueBiochem @PUCancerCenter @Purdue Congratulations @KyleCottrell !!

[Fyodor Urnov @UrnovFyodor]

ASTONISHING+EXHILARATING:
31 patients with SCD free of pain post-CRISPR-gene-editing!
42/44 with thal are transfusion-free!!
AND approach being advanced to to the pediatric population!!!
Bravo, @CRISPRTX CMC team.
♥️ 👏 Stu Orkin + @danielevanbauer
https://t.co/r7DSlwjQXJ

[CRISPR Therapeutics @CRISPRTX]

We are pleased to announce new clinical data on our investigational gene-edited therapy for the treatment of sickle cell disease and beta thalassemia at the @EHA_Hematology 2022 Congress. Learn more: https://t.co/AUpiyc1vQB #EHA2022

[CRISPR Therapeutics @CRISPRTX]

We’re pleased to share that an abstract on safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for an oral presentation at the @EHA_Hematology 2022 Congress. Learn more: https://t.co/IaQYijzwNZ #EHA2022

[Hemangi Chaudhari @hemangi_c]

@DruleyLab @MissionBio Congratulations!!

[David R. Liu @davidrliu]

Today we report in @CellCellPress an engineered virus-like particle (eVLP) platform that mediates efficient in vivo delivery of therapeutic proteins, including base editors and Cas9 nuclease, resulting in therapeutic editing in multiple mouse organs. 1/14
https://t.co/v1yBl296L6

[David R. Liu @davidrliu]

Wow.
“4 genes were knocked out…including one that encodes a molecule that causes an aggressive human rejection response.
A growth gene was also inactivated to prevent the pig’s heart from continuing to grow…6 human genes were inserted…to make the porcine organs more tolerable”

[Hemangi Chaudhari @hemangi_c]

@claricehongky @genomeresearch @BarakACohen Congratulations Clarice!

[Jon Epstein Lab @JonEpsteinLab]

Therapeutic mRNA for heart failure?!

Our own Joel Rurik (@DevBioAcademic) teamed up with @WeissmanLab to make CAR T cells entirely in the body to treat heart disease.

Published today on the cover of Science!
https://t.co/f3UZrNikNs

@CAMBUpenn @PennBGS @ScienceMagazine

1/6

[Hemangi Chaudhari @hemangi_c]

@maxvstaller @CellSystemsCP Congratulations Max!

[LabHopping @labhopping]

🔊In a few days, we head to the printers' to print the first batch of orders. If you want to be among the first receivers of the new #LabhoppingCalendar this month, then don't wait. Book your copy at 15% discount & free shipping now! Link: https://t.co/9RO6WEcsY1

[Hemangi Chaudhari @hemangi_c]

@SD_Ackerman Looks amazing! Congratulations Sarah! Love the community page!

[CRISPR Therapeutics @CRISPRTX]

We are pleased to announce that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™ for the treatment of relapsed or refractory CD19+ B-cell malignancies. Learn more here: https://t.co/P6b6IUDcEO

[Hemangi Chaudhari @hemangi_c]

@kernytsky Oh th#ats beautiful!